Mast Cell Deficiency Limits the Development of Chronic Rhinosinusitis in XXXX .

@entity1 @entity1712 @entity19 @entity1373 @entity102
BACKGROUND: @entity102 ( @entity102 ) is one of the most common @entity102 in adults in both developing and developed countries. The etiology and pathogenesis of @entity102 remain poorly understood, and the disease is refractory to therapy in many @entity1 . Mast cell activation has been demonstrated in the sinonasal mucosa of @entity1 with @entity102 ; however, the specific contribution of mast cells to the development and pathogenesis of this disease has not been established. OBJECTIVE: The objective of this study was to investigate the role of mast cells in the development of @entity102 . METHODS: C57BL/6 wild-type and C57BL/6-Kit(W-sh/W-sh) mast cell-deficient @entity19 were immunized by intraperitoneal allergen injection and subsequent chronic low dose intranasal allergen challenges. The sinonasal phenotypes of these groups were then evaluated and compared to saline-treated controls using radiologic, histologic, and immunologic methods. RESULTS: Wild-type @entity19 exposed to chronic intranasal allergen developed many features seen in @entity1 @entity102 , including mucosal thickening, cystic changes, polyp development, @entity1712 , @entity1373 , and mast cell activation. In contrast, sinonasal pathology was significantly attenuated in mast cell-deficient @entity19 subjected to the same chronic allergen protocol. Specifically, tissue @entity1712 and @entity1373 were reduced by approximately 50% compared to wild-type levels. Surprisingly, none of the mast cell-deficient @entity19 subjected to chronic allergen challenge developed cystic changes or polypoid changes in the nose or sinuses. CONCLUSIONS: These data identify a critical role for mast cells in the development of many features of a @entity19 model of @entity1712 , suggesting that therapeutic strategies targeting mast cells be examined in @entity1 afflicted with this disease.
